US3681497A - Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide - Google Patents

Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide Download PDF

Info

Publication number
US3681497A
US3681497A US641160A US3681497DA US3681497A US 3681497 A US3681497 A US 3681497A US 641160 A US641160 A US 641160A US 3681497D A US3681497D A US 3681497DA US 3681497 A US3681497 A US 3681497A
Authority
US
United States
Prior art keywords
isoergolenyl
methyl
diethyl
hydrogen maleate
carbamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US641160A
Inventor
Miroslav Semonsky
Viktor Zikan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spofa Vereinigte Pharma Werke
Original Assignee
Spofa Vereinigte Pharma Werke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spofa Vereinigte Pharma Werke filed Critical Spofa Vereinigte Pharma Werke
Application granted granted Critical
Publication of US3681497A publication Critical patent/US3681497A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

Definitions

  • D i.v. s.c. oral mice 14.4 mg/kg 82 mg/kg 90 mg/kg rats 1.5 mg/kg 3 mg/kg 12.5 mg/kg It has been established that the clinical therapeutic oral dose of Lysenyl for humans amounts to 0.00125 mg/kg daily and is therefore about a l/70,000 (one seventy-thousandth part) of the oral LD in mice, or about 1/ 10,000 (one ten-thousandth part) of the corresponding dose in rats.
  • Chronic Toxicity The chronic toxicity was investigated in rats which received daily doses of 0.005 mg/kg or 0.025 mg/kg s.c. for three months and in a second series of tests, the same doses for 6 months. Data obtained at the conclusion of these tests, when compared with the data from the control animals, did not reveal any alterations which could be regarded as signs of undesirable or toxic effects of Lysenyl. The data included blood counts, biochemical determinations, histological stu dies, growth studies, etc.
  • the preparation was administered orally in a very low dosage, on the average 25 mcg was administered twice daily, at the most 25 mcg was given three times daily.
  • This dosage is only l/40th of that usually given for methysergide, making Lysenyl a more effective preparation with respect to the dosage necessary to produce the desired action when compared to the most widely heretofore used preparation. Lysenyl, similarly to methysergide, is suited for long-term therapy but not for the suppression of an attack already developed.
  • Lysenyl The antiallergic effectiveness of Lysenyl was further established by the preventive oral administration of 25mcg of the drug three-fourths to 1 hour before intracutaneous testing of inhalation allergens. In comparison with the control group, a partial inhibition of the local reaction was observed. The average diameter of the local reaction areola was diminished by 7.8 mm (Lysenyl 11.0 mm, control 18.8 mm).
  • the Dumping Syndrome The symptoms of the post-resection syndrome, especially the increased rate of intestinal passage, can be considered as consequences of an increased production and release of serotonin in the small intestine.
  • Lysenyl was administered in preliminary trials to 9 patients, following surgery for resection of the stomach, and who suffered from a pronounced post-resection syndrome. These outpatients received low doses during the first week which were gradually increased thereafter to doses of 75 200 mcg daily.
  • the therapeutic effect manifested itself as early as after 24 hours in 6 patients of the 9 by a suppression of the diarrhea, and in the course of the first week of the therapy, the condition of two further patients improved.
  • the renal blood flow (clearance of para aminohippuric acid) and the glomerular filtration rate (clearance of inulin) were determined before and after the treatment in addition to all of the above recited analyses.
  • Lysenyl In comparison to the frequency of undesirable side effects seen with the use of methysergide, the side effects of Lysenyl are sigiificantly less in number and severity.
  • Tablets were prepared according to the usual procedure for the preparation of tablets for pharmaceutical use.
  • EXAMPLE II The dosage used in combination of Lysenyl with antihistamines; Lysenyl 25 mcg Bromadryl mebrophenhydramine hydrochloride) 25 mg twice to threev times daily, or Lysenyl 25 mcg Medrin mebrophenhydrinate) 25 mg twice to three times daily.
  • Lysenyl is, with respect to the size of the clinically effective dosage, the most active of the known serotonin antagonists.
  • a method of relieving vascular headaches of a pa tient suffering from migraine which comprises administering to such patient N-(D-6-methyl-8-isoergolenyl)-N,N'-diethyl-carbamide hydrogen maleate in a dose of 25 mcg two to three times daily, said N-(D-6- methyl-8-isoergolenyl )-N' ,N -diethylcarbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
  • a method of treating a patient for suppressing or mitigating the development of allergic reactions to an allergic stimulus which comprises orally administering to such patient N-(D-6-methyl-8-isoergolenyl)- N, N-
  • diethyl-carbamide hydrogen maleate in a dose of 25 mcg two to three times daily, said N-(D-6-methyl-8- isoergolenyl)--N,N-diethyl-carbamide hydrogen maleate acting as a specific sertonin antagonist to excessive production of serotonin.
  • a method of treating a patient for suppressing or mitigating the development of urticaria or Quinckes edema in response to an allergic stimulus which comprises orally administering to such patient N-(D-6- methyl- 8-isoergolenyl )-N' ,N -diethyl-carbarnide hydrogen maleate in a dose of 35 mcg two to three times daily, said N-(D-6-methyl-8-isoergolenyl)-N,N- diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of sertonin.
  • N-(D-6- methyl-S-isoergolenyl)-N',N'-diethyl-carbamide hydrogen maleate is administered together with 25 mg of another antihistamine, each of said agents being administered two to three times daily, said N-(D-6- methyl-S-isoergolenyl )-N' ,N'-diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
  • antihistamine is a member selected from the group consisting of mebrophenhydramine and mebrophenhydrinate.
  • a method of treating hypertension which com prises orally administering to a hypertensive patient N- (D-6-methyl-8-isoergolenyl)-N',N-diethyl-carbamide hydrogen maleate in a dosage of about 25 mcg twice daily, said N-(D6-methyl-8-isoergolenyl)-N',N- diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Method of using N-(D-6-methyl-8-isoergolenyl)-N'', N''diethylcarbamide hydrogen maleate in the therapeutic treatment of migraine headache, urticaria, hypertension and allergic conditions, in the last case along or in the form of an enhanced effect when administered together with an anti-histamine.

Description

ilnited States atent Semonsky et a1.
[54] THERAPEUTIC METHODS OF EMPLOYING HYDROGEN MALEATE SALT OF N-(D-6-METHYL-8- ISOERGOLENYL)-N,N'-DIETHYL- CARBAMIDE [72] Inventors: Miroslav Semonsky'; Viktor Zikan,
both of Prague, Czechoslovakia [73] Assignee: Spofa Spojene Podniky Pro Zdravotnick-on Vyrobu, Prague, Czechoslovakia [22] Filed: May 25, 1967 [21] Appl. No.2 641,160
[30] Foreign Application Priority Data June 7, 1966 Czechoslovakia ..3860/66 [52] US. Cl ..424/261 [51] Int. Cl. ..A6lk 27/00 [58] Field of Search ..424/261; 260/285.5
[56] References Cited UNITED STATES PATENTS 3,218,324 11/1965 Hofmann et al. ..424/261 3,228,944 l/l966 Bernardi et a1. ..260/285.5
3,238,211 3/1966 Camerino et al. ..260/285.5
FOREIGN PATENTS OR APPLICATIONS 100,832 9/1961 Czechoslovakia OTHER PUBLICATIONS Rysanek et al.; Chem Abst. Vol 63 (1965) page 6221h I Votava et al.; Chem Abst. Vol. 59 (1963), Page 9221d Votava et al.; Chem. Abst. Vol. 62 (1965) page 15307h etc.
Cerny et al.; Chem. Abst. Vol. 59 (1963) page 7581d etc.
Spofa; Chem. Abst. Vol. 57 (1962) page 15005f Grollman; Pharmacology and Therapeutics, 1965, Publisher Lea & Febiger, pages 244- 247 Primary Examine rSam Rosen Att0rneyMichael S. Striker 5 7 ABSTRACT Method of using N-(D-6-methyl-8-isoergolenyl)-N, N'-diethylcarbamide hydrogen maleate in the therapeutic treatment of migraine headache, urticaria, hypertension and allergic conditions, in the last case along or in the form of an enhanced effect when administered together with an anti-histamine.
6 Claims, No Drawings N-CH COOH
coon
Clinical tests carried out with Lysenyl establish that the same constitutes a specific serotonin antogonist and can be employed as a medicament in those conditions and diseases, caused or aggravated by serotonin.
It has also been established by appropriate pharmacological tests that the administration of Lysenyl as compared with analogous preparations produces little or no undesirable side effects i.e., the compound in the free base form or salt form is substantially non-toxic.
The following table represents the data obtained in taxicity studies with Lysenyl.
TOXICITY OF LYSENYL Acute Toxicity:
D i.v. s.c. oral mice 14.4 mg/kg 82 mg/kg 90 mg/kg rats 1.5 mg/kg 3 mg/kg 12.5 mg/kg It has been established that the clinical therapeutic oral dose of Lysenyl for humans amounts to 0.00125 mg/kg daily and is therefore about a l/70,000 (one seventy-thousandth part) of the oral LD in mice, or about 1/ 10,000 (one ten-thousandth part) of the corresponding dose in rats.
Chronic Toxicity The chronic toxicity was investigated in rats which received daily doses of 0.005 mg/kg or 0.025 mg/kg s.c. for three months and in a second series of tests, the same doses for 6 months. Data obtained at the conclusion of these tests, when compared with the data from the control animals, did not reveal any alterations which could be regarded as signs of undesirable or toxic effects of Lysenyl. The data included blood counts, biochemical determinations, histological stu dies, growth studies, etc.
The administration of daily oral doses of 0.01 mg/kg to pregnant rats for the entire duration of the pregnancy did not cause any significant increase of the incidence of fetus resorption. The delivered ofispring were alive and free from developmental abnormalities.
The following clinical studies were carried out in order to evaluate the effectiveness of Lysenyl. a. Migraine A comprehensive evaluation of results obtained in several different clinics with the therapeutic administration of Lysenyl in cases of vascular headache of the migraineous type was carried out. The evaluation establishes that in a sample comprising 144 patients the following results are obtained:
1. in 73 (50.7 percent) of the patients, either a complete disappearance of migraineous attacks, or a very substantial amelioration (a very marked decrease of the intensity and frequency of the attacks);
2. in 47 (32.6 percent) patients, an amelioration;
3. in 24 (16.7 percent) patients, no apparent effect.
A beneficial efiect was therefore observed in approximately 83 percent of patients.
The preparation was administered orally in a very low dosage, on the average 25 mcg was administered twice daily, at the most 25 mcg was given three times daily. This dosage is only l/40th of that usually given for methysergide, making Lysenyl a more effective preparation with respect to the dosage necessary to produce the desired action when compared to the most widely heretofore used preparation. Lysenyl, similarly to methysergide, is suited for long-term therapy but not for the suppression of an attack already developed.
b. Allergic Conditions In accordance with the recently established concepts of the participation of serotonin in the pathogenesis of allergic conditions, Lysenyl was also evaluated in various allergic diseases (urticaria and Quinckes edema, eczema, bronchial asthma, vasomotor rhinitis, etc.), and mostly in such cases which were resistant against the usual antiallergic therapy (antihistamines, desensitization). The dosage used amounted to 25 mcg twice to three times daily. The obtained results were very good, in some cases even surprising, specifically when Lysenyl was administered together i.e., in combination with known antihistamines and thus the combined therapeutic activities of the respective components, i.e., the antihistamine and the antiserotonin effect, could be brought about at the same time. The best results were achieved in the urticaria and Quinckes edema while the eflect in vasomotoric rhinitis was relatively weaker.
The antiallergic effectiveness of Lysenyl was further established by the preventive oral administration of 25mcg of the drug three-fourths to 1 hour before intracutaneous testing of inhalation allergens. In comparison with the control group, a partial inhibition of the local reaction was observed. The average diameter of the local reaction areola was diminished by 7.8 mm (Lysenyl 11.0 mm, control 18.8 mm).
c. The Dumping Syndrome The symptoms of the post-resection syndrome, especially the increased rate of intestinal passage, can be considered as consequences of an increased production and release of serotonin in the small intestine. In accordance with this concept, Lysenyl was administered in preliminary trials to 9 patients, following surgery for resection of the stomach, and who suffered from a pronounced post-resection syndrome. These outpatients received low doses during the first week which were gradually increased thereafter to doses of 75 200 mcg daily. The therapeutic effect manifested itself as early as after 24 hours in 6 patients of the 9 by a suppression of the diarrhea, and in the course of the first week of the therapy, the condition of two further patients improved. The patients noted that at the same time as the frequency of stools diminished, the disappearance of the feeling of abdominal tension, an increase of the appetite, and an improvement of both physical and psychical condition.
Tolerability. In a long-term clinical study aimed at the pharmacological investigation of Lysenyl, the preparation was administered to 56 hypertensive patients for 3 14 months. The initial dosage, l2.5 mcg daily, was gradually increased to an average dosage of 25 mcg three times daily. in all patients, the following analyses were carried out before the treatment, once a month during treatment, and three months after termination of treatment; examination of the urine and urine sediment, creatinine clearance, non-protein nitrogen, blood count, sedimentation of erythrocytes, and electro-cardiogram.
in 26 patients treated for more than 6 months, at the intervals set forth above, the following additional analyses were carried out: serum bilirubin, thymol turbidity reaction, SGPT (serum glutamate-pyruvate transarninase) phosphatase, and glycernia on an empty stomach.
In 8 patients treated for more than 8 months, the renal blood flow (clearance of para aminohippuric acid) and the glomerular filtration rate (clearance of inulin) were determined before and after the treatment in addition to all of the above recited analyses.
All values established throughout the testing were compared with those values found before the treatment and were found to have remained without pathological changes. In the majority of those patients who had had proteinuria before the treatment, the latter disappeared completely in the course of the therapy.
Blood pressure decreased during the monotherapy with Lysenyl especially in patients in the initial stages of hypertension marked by a moderately high diastolic pressure. During treatment a number of subjective complaints either disappeared or were substantially alleviated, especially headache and cephalernia. A comprehensive evaluation of reports from all of the clinical studies carried out reveals that side effects were ob served in about percent of cases. The most frequent side effects were nausea, a feeling of lassitude, nasal stifiiness, and dryness in the mouth; less frequent side effects were vomiting or a slight vertigo. Diarrhea was encountered only sporadically (in patients with migraine and allergy). Headache was seen only infrequently (in those patients with the dumping syndrome). All these side effects were transient and disappeared as soon as the dosage had been decreased. Only in quite exceptional cases did the therapy have to be discontinued. The majority of the observed side effects developed in such cases where the therapy had been started with a full dosage (25 mcg three times daily), and their frequency fell to a minimum when the optimum dosage scheme was used, i.e., when the dosage was gradually increased.
In comparison to the frequency of undesirable side effects seen with the use of methysergide, the side effects of Lysenyl are sigiificantly less in number and severity.
The following Examples illustrate pharmaceutical preparations for use in the practice of this invention, but the same are not to be consuued as a limitation thereof.
EXAMPLE 1 Tablets of the formula:
milligram Lysenyl 0.025 Lactose 97.875 Corn starch l 1.00 Magnesium stearate 1.1
Total weight 110.000
Tablets were prepared according to the usual procedure for the preparation of tablets for pharmaceutical use.
EXAMPLE II The dosage used in combination of Lysenyl with antihistamines; Lysenyl 25 mcg Bromadryl mebrophenhydramine hydrochloride) 25 mg twice to threev times daily, or Lysenyl 25 mcg Medrin mebrophenhydrinate) 25 mg twice to three times daily.
The results of the clinical tests permit the following conclusions:
1. Lysenyl is, with respect to the size of the clinically effective dosage, the most active of the known serotonin antagonists.
2. it is the drug of choice for the long-term therapy of vascular headache of the migraine type.
3. In allergic conditions, it substantially enhances, by
its antiserotonin activity, the therapeutical usefulness of antihistamines.
4. In the dumping syndrome it exerts a reliable blocking effect upon the untoward action of serotonin on the intestinal motility.
5. Side effects observed during the therapy with Lysenyl are, in comparison with analogous preparations, both of less intensity and of lesser frequency and they are practically negligible if an appropriate dosage scheme is used.
We claim:
I. A method of relieving vascular headaches of a pa tient suffering from migraine which comprises administering to such patient N-(D-6-methyl-8-isoergolenyl)-N,N'-diethyl-carbamide hydrogen maleate in a dose of 25 mcg two to three times daily, said N-(D-6- methyl-8-isoergolenyl )-N' ,N -diethylcarbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
2. A method of treating a patient for suppressing or mitigating the development of allergic reactions to an allergic stimulus which comprises orally administering to such patient N-(D-6-methyl-8-isoergolenyl)- N, N-
diethyl-carbamide hydrogen maleate in a dose of 25 mcg two to three times daily, said N-(D-6-methyl-8- isoergolenyl)--N,N-diethyl-carbamide hydrogen maleate acting as a specific sertonin antagonist to excessive production of serotonin.
3. A method of treating a patient for suppressing or mitigating the development of urticaria or Quinckes edema in response to an allergic stimulus which comprises orally administering to such patient N-(D-6- methyl- 8-isoergolenyl )-N' ,N -diethyl-carbarnide hydrogen maleate in a dose of 35 mcg two to three times daily, said N-(D-6-methyl-8-isoergolenyl)-N,N- diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of sertonin.
4. Method according to claim 3 wherein said N-(D-6- methyl-S-isoergolenyl)-N',N'-diethyl-carbamide hydrogen maleate is administered together with 25 mg of another antihistamine, each of said agents being administered two to three times daily, said N-(D-6- methyl-S-isoergolenyl )-N' ,N'-diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
5. Method according to claim 4 wherein said antihistamine is a member selected from the group consisting of mebrophenhydramine and mebrophenhydrinate.
6. A method of treating hypertension which com prises orally administering to a hypertensive patient N- (D-6-methyl-8-isoergolenyl)-N',N-diethyl-carbamide hydrogen maleate in a dosage of about 25 mcg twice daily, said N-(D6-methyl-8-isoergolenyl)-N',N- diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.

Claims (5)

  1. 2. A method of treating a patient for suppressing or mitigating the development of allergic reactions to an allergic stimulus which comprises orally administering to such patient N-(D-6-methyl-8-isoergolenyl)- N'', N''-diethyl-carbamide hydrogen maleate in a dose of 25 mcg two to three times daily, said N-(D-6-methyl-8-isoergolenyl)--N'',N''-diethyl-carbamide hydrogen maleate acting as a specific sertonin antagonist to excessive production of serotonin.
  2. 3. A method of treating a patient for suppressing or mitigating the development of urticaria or Quincke''s edema in response to an allergic stimulus which comprises orally administering to such patient N--(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate in a dose of 35 mcg two to three times daily, said N-(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of sertonin.
  3. 4. Method according to claim 3 wherein said N-(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate is administered together with 25 mg of another antihistamine, each of said agents being administered two to three times daily, said N-(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
  4. 5. Method according to claim 4 wherein said antihistamine is a member selected from the group consisting of mebrophenhydramine and mebrophenhydrinate.
  5. 6. A method of treating hypertension which comprises orally administering to a hypertensive patient N-(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate in a dosage of about 25 mcg twice daily, said N-(D-6-methyl-8-isoergolenyl)-N'',N''-diethyl-carbamide hydrogen maleate acting as a specific serotonin antagonist to excessive production of serotonin.
US641160A 1966-06-07 1967-05-25 Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide Expired - Lifetime US3681497A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS386066 1966-06-07

Publications (1)

Publication Number Publication Date
US3681497A true US3681497A (en) 1972-08-01

Family

ID=5379923

Family Applications (1)

Application Number Title Priority Date Filing Date
US641160A Expired - Lifetime US3681497A (en) 1966-06-07 1967-05-25 Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide

Country Status (1)

Country Link
US (1) US3681497A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953454A (en) * 1971-08-05 1976-04-27 Spofa, United Pharmeceutical Works N-(D-6-methyl-8-isoergoline-I-yl)-N',N'-diethylurea
US3954988A (en) * 1973-11-24 1976-05-04 Schering Aktiengesellschaft Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects
US4096266A (en) * 1976-04-06 1978-06-20 Hzi Research Center Lisuride in alcoholism
US4379790A (en) * 1979-06-13 1983-04-12 Schering Aktiengesellschaft (Erolinyl)-N,N-diethylurea derivatives, and their preparation and use
WO1983003758A1 (en) * 1982-05-03 1983-11-10 Schering Aktiengesellschaft Pharmaceutical composition having a cystostatic activity
WO1983003759A1 (en) * 1982-05-03 1983-11-10 Schering Aktiengesellschaft Synergic combination with cytostatic activity
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3218324A (en) * 1956-05-18 1965-11-16 Sandoz Ltd 1-methyl ergotamines and ergocornines
US3228944A (en) * 1966-01-11 Lumiergoline derivatives
US3238211A (en) * 1966-03-01 Derhvatives of g-methyl and i,g-dimethyl ergolhne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228944A (en) * 1966-01-11 Lumiergoline derivatives
US3238211A (en) * 1966-03-01 Derhvatives of g-methyl and i,g-dimethyl ergolhne
US3218324A (en) * 1956-05-18 1965-11-16 Sandoz Ltd 1-methyl ergotamines and ergocornines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cerny et al.; Chem. Abst. Vol. 59 (1963) page 7581d etc. *
Grollman; Pharmacology and Therapeutics, 1965, Publisher Lea & Febiger, pages 244 247 *
Rysanek et al.; Chem Abst. Vol 63 (1965) page 6221h *
Spofa; Chem. Abst. Vol. 57 (1962) page 15005f *
Votava et al.; Chem Abst. Vol. 59 (1963), page 9221d *
Votava et al.; Chem. Abst. Vol. 62 (1965) page 15307h etc. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953454A (en) * 1971-08-05 1976-04-27 Spofa, United Pharmeceutical Works N-(D-6-methyl-8-isoergoline-I-yl)-N',N'-diethylurea
US3954988A (en) * 1973-11-24 1976-05-04 Schering Aktiengesellschaft Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects
US4096266A (en) * 1976-04-06 1978-06-20 Hzi Research Center Lisuride in alcoholism
US4379790A (en) * 1979-06-13 1983-04-12 Schering Aktiengesellschaft (Erolinyl)-N,N-diethylurea derivatives, and their preparation and use
WO1983003758A1 (en) * 1982-05-03 1983-11-10 Schering Aktiengesellschaft Pharmaceutical composition having a cystostatic activity
WO1983003759A1 (en) * 1982-05-03 1983-11-10 Schering Aktiengesellschaft Synergic combination with cytostatic activity
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride

Similar Documents

Publication Publication Date Title
Parkes et al. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
US4507323A (en) Treatment of psychosexual dysfunctions
CA2219502C (en) Methods and formulations for modulating the human sexual response
JP2005527599A (en) Use of zonisamide in obesity and eating disorders
JPS61277620A (en) Dysuria therapy
JP3806427B2 (en) New painkiller
EP1704860B1 (en) Benzamidine derivatives for treatment and prevention of mucositis
US3681497A (en) Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide
Donker et al. Infusion of angiotensin-II analogue in two patients with unilateral renovascular hypertension
JP2872809B2 (en) Pharmaceutical composition suitable for treating Parkinson's disease, comprising monosialoganglioside GM <1> or a derivative thereof
US5073555A (en) Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels
EP0581904A1 (en) Method of inhibiting fibrosis.
US20200170990A1 (en) Method for treating schnitzler's syndrome
AU2002363874A1 (en) Use of desoxypeganine for treating clinical depression
US5534523A (en) Anti-aids virus composition
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
US9339458B2 (en) Use of vaginal insulin sensitizing agents
US20240269104A1 (en) Method for treating parkinson's disease
JP2586542B2 (en) A therapeutic agent for cattle abomasum displacement
US3904758A (en) Method of increasing wakefulness
JP3151217B2 (en) Uses of Atipamezole for the treatment of male or male impotence
CN114632083A (en) Compound preparation for treating cold and cough and preparation method thereof
WO2024033946A1 (en) Compositions and use in methods for treating a cognitive deficit
TW202120116A (en) Therapeutic agent or prophylactic agent for fibromyalgia
CN116036102A (en) Use of Manacastine to reduce intestinal damage caused by XELOX combination treatment regimen